Lenox Wealth Advisors Inc. Buys 6 Shares of Johnson & Johnson (JNJ)

Investors purchased 1,957 call options on the company. Schaper Benz & Wise Investment Counsel Wi reported 0.19% stake. Hedeker Wealth holds 18,676 shares. Hamilton Point Invest Advisors Ltd Liability Com stated it has 32,660 shares or 2.32% of all its holdings. Fjarde Ap invested in 30,145 shares. Morgan Stanley reported 21.13M shares. Mark Sheptoff Finance Planning Limited Liability reported 4.9% in Johnson & Johnson (NYSE:JNJ). This represents a $3.36 dividend on an annualized basis and a yield of 2.58%. Whirlpool Corp. (NYSE:WHR) was raised too.

Community Bank, which manages about $456.05 million US Long portfolio, decreased its stake in Spdr Tech Select Sector Etf (XLK) by 7,500 shares to 7,219 shares, valued at $349,000 in 2016Q4, according to the filing. Cibc Ww Markets Corp owns 11,844 shares.

Analysts await Independence Holding Company (NYSE:IHC) to report earnings on August, 7. The stock of AbbVie Inc (NYSE:ABBV) has "Sell" rating given on Wednesday, April 6 by Societe Generale. On Monday, October 5 the stock rating was reinitiated by Piper Jaffray with "Neutral". The rating was maintained by FinnCap on Monday, August 17 with "Corporate". Citigroup has " rating and $60 target. Canaccord Genuity initiated the stock with "Buy" rating in Monday, September 19 report. Jefferies maintained the stock with "Hold" rating in Thursday, August 4 report.

Since January 1, 0001, it had 0 insider buys, and 5 sales for $14.98 million activity.

Johnson & Johnson (NYSE:JNJ) on Thursday closed at $128.78. RSI is a technical indicator of price momentum, comparing the size of recent gains to the size of recent losses and establishes oversold and overbought positions. 14,543 shares valued at $1.78 million were sold by Kapusta Ronald A on Tuesday, February 28. $2.58M worth of stock was sold by Stoffels Paulus on Wednesday, February 15. Villere St Denis J invested 2.11% in Euronet Worldwide, Inc. Analysts have a mean recommendation of 2.50 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).

Ratings analysis reveals 47% of Johnson & Johnson's analysts are positive. Equities analysts anticipate that Johnson & Johnson will post $7.11 earnings per share for the current fiscal year. The firm has "Outperform" rating given on Wednesday, July 20 by RBC Capital Markets. The rating was upgraded by Citigroup to "Buy" on Friday, October 28. The stock has a consensus rating of "Hold" and an average price target of $130.90. UBS has "Buy" rating and $144.0 target.

01/26/2017 - Johnson & Johnson was downgraded to "market perform" by analysts at Wells Fargo. Jefferies has "Hold" rating and $115 target. The stock has "Outperform" rating by Cowen & Co on Tuesday, August 25. The rating was upgraded by Barclays Capital on Tuesday, December 1 to "Overweight". The firm earned "Neutral" rating on Wednesday, April 20 by Goldman Sachs. As per Wednesday, July 20, the company rating was upgraded by Argus Research. THNS's SI was 24,100 shares in June as released by FINRA.

Investors sentiment increased to 0.94 in Q4 2016. Its up 0.12, from 0.82 in 2016Q3. It is positive, as 63 investors sold JNJ shares while 834 reduced holdings. 114 funds opened positions while 731 raised stakes. Intrust Bank & Trust Na invested 1.2% of its portfolio in Johnson & Johnson (NYSE:JNJ).

Johnson & Johnson (NYSE:JNJ) 52-week high price stands at $129.00 and low price stands at $109.32, its price distance from 52-week high is -0.17% while its distance from 52-week low price is 17.8%. Weatherly Asset LP accumulated 56,264 shares. Salem Counselors owns 173,522 shares. Cidel Asset Mgmt holds 0.98% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 170,791 shares.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Fool.com which released: "The Definitive Guide to Johnson & Johnson Stock Dividends" on June 02, 2017, also Barrons.com with their article: "Johnson & Johnson Faces FDA Headwind" published on May 17, 2017, Reuters.com published: "Johnson & Johnson offers European Union concessions over Actelion deal" on May 18, 2017. HCP, Inc. (NYSE:HCP), at its latest closing price of $31.47, it has a price-to-book ratio of 2.67, compared to an industry average at 4.33. Wallace Mgmt holds 105,608 shares.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Seekingalpha.com which released: "Protagonist No Enemy To Johnson & Johnson's Digestive Disease Aims" on June 01, 2017, also Reuters.com with their article: "Johnson & Johnson offers European Union concessions over Actelion deal" published on May 18, 2017, Fiercebiotech.com published: "Johnson & Johnson commits $990M to land Protagonist's oral Crohn's drug" on May 30, 2017. Thomas J. Herzfeld Advisors Inc. bought a new stake in Johnson & Johnson during the fourth quarter valued at $117,000. Piermont Capital Incorporated reported 15,290 shares. Spinnaker Tru holds 1.18% or 76,349 shares. Lenox Wealth Advisors Inc. now owns 871 shares of the company's stock valued at $108,000 after buying an additional 6 shares during the period.

  • Zachary Reyes